Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party ; day:18 ; month:10 ; year:2024 ; pages:1
Bone marrow transplantation ; (18.10.2024), 1

Creator: Penack, Olaf
Peczynski, Christophe
Boreland, William
Lemaitre, Jessica
Reinhardt, H. Christian
Afanasyeva, Ksenia
Avenoso, Daniele
Holderried, Tobias A. W.
Kornblit, Brian Thomas
Gavriilaki, Eleni
Martinez, Carmen
Chiusolo, Patrizia
Mico, Maria Caterina
Daguenet, Elisabeth
Wichert, Stina
Ozdogu, Hakan
Piekarska, Agnieszka
Kinsella, Francesca
Basak, Grzegorz W.
Schoemans, Hélène
Könecke, Christian
Moiseev, Ivan
Peric, Zinaida

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41409-024-02435-8

URN: urn:nbn:de:101:1-2501072106183.346634965769

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Penack, Olaf
Peczynski, Christophe
Boreland, William
Lemaitre, Jessica
Reinhardt, H. Christian
Afanasyeva, Ksenia
Avenoso, Daniele
Holderried, Tobias A. W.
Kornblit, Brian Thomas
Gavriilaki, Eleni
Martinez, Carmen
Chiusolo, Patrizia
Mico, Maria Caterina
Daguenet, Elisabeth
Wichert, Stina
Ozdogu, Hakan
Piekarska, Agnieszka
Kinsella, Francesca
Basak, Grzegorz W.
Schoemans, Hélène
Könecke, Christian
Moiseev, Ivan
Peric, Zinaida
SpringerLink (Online service)

Other Objects (12)

$ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party$

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

$Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials$

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

$Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD$

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

$Ruxolitinib in steroid refractory graft-vs.-host disease: a case report$

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

Graffiti | Streetart

eCP

$Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)$

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

$Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)$

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

$Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease$

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

$Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study$

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

$ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party$

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

$Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials$

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

$Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD$

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

$Ruxolitinib in steroid refractory graft-vs.-host disease: a case report$

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

Graffiti | Streetart

eCP

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

$Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease$

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

$Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study$

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

$ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party$

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

$Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials$

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

$Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD$

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

$Ruxolitinib in steroid refractory graft-vs.-host disease: a case report$

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

Graffiti | Streetart

eCP

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

$Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease$

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

$Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study$

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

eCP

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

eCP

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

eCP

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

Related objects

Reset password